Similar efficacy, safety and immunogenicity of adalimumab biosimilar BI 695501 and Humira reference product in patients with moderately to severely active rheumatoid arthritis: results from the phase III randomised VOLTAIRE-RA equivalence study

摘要

Objective To demonstrate clinical equivalence of adalimumab biosimilar candidate BI 695501 with Humira.